RedHill Biopharma (RDHL) Debt to Equity (2016 - 2022)
Historic Debt to Equity for RedHill Biopharma (RDHL) over the last 3 years, with Q4 2022 value amounting to -$4.76.
- RedHill Biopharma's Debt to Equity fell 15053.07% to -$4.76 in Q4 2022 from the same period last year, while for Dec 2022 it was -$4.76, marking a year-over-year decrease of 15053.07%. This contributed to the annual value of -$4.76 for FY2022, which is 15053.07% down from last year.
- Per RedHill Biopharma's latest filing, its Debt to Equity stood at -$4.76 for Q4 2022, which was down 15053.07% from $9.42 recorded in Q4 2021.
- RedHill Biopharma's Debt to Equity's 5-year high stood at $9.42 during Q4 2021, with a 5-year trough of -$4.76 in Q4 2022.
- Its 3-year average for Debt to Equity is $3.51, with a median of $5.87 in 2020.
- As far as peak fluctuations go, RedHill Biopharma's Debt to Equity surged by 6050.21% in 2021, and later plummeted by 15053.07% in 2022.
- RedHill Biopharma's Debt to Equity (Quarter) stood at $5.87 in 2020, then soared by 60.5% to $9.42 in 2021, then crashed by 150.53% to -$4.76 in 2022.
- Its Debt to Equity was -$4.76 in Q4 2022, compared to $9.42 in Q4 2021 and $5.87 in Q4 2020.